July 2017 By Tim Horn INTRODUCTION The antiretroviral (ARV) pipeline remains robust, with several drugs, coformulations, and biologics currently in Phase II and III stages of development. The trends are clear: maximizing the safety and efficacy of standard three-drug regimens;…
Objectives for Module 1: Discuss the difference between HIV prevention for HIV-negative people, HIV prevention for people living with HIV, and HIV testing Discuss the evidence-based HIV prevention options we have available Overview of new tools in development In many…
Objectives for Module 2: Discuss what HEALTH INDICATORS are, what they are not, and why they are important Look at some of the current indicators and relevant research to see how well we’re doing with HIV prevention in key populations…
Objectives for Module 3: Discuss examples of “structural determinants” and “social determinants” of health that drive the HIV epidemic Discuss the difference between individual, structural, and social interventions Look at examples of structural and social interventions for HIV prevention Current…
Objectives for Module 4: Review a brief history of HIV/AIDS policy advocacy Understand basic tactics for policy advocacy and how it differs from other kinds of advocacy Go over suggestions for developing an advocacy agenda and action plan Discuss some…
TAG’s strong financial health and commitment to accountability and transparency have earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator.
On May 3, 2017, Treatment Action Group (TAG) and the DARE Collaboratory Community Advisory Board held a community webinar to provide an update on research results presented at the Conference in Retroviruses and Opportunistic Infections (CROI). The webinar was presented by TAG's Basic…
Statement condemning passage of the American Health Care Act (AHCA) today by the House of Representatives and calls for critical community action as the dangerous bill now heads to Senate.
With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.
Dear Majority Leader McConnell, Minority Leader Schumer, Speaker Ryan, and Democratic Leader Pelosi: We the undersigned urge Congress to reject devastating funding cuts to the National Institutes of Health (NIH) proposed under the President’s Fiscal Year (FY) 2018 “skinny budget,” released on March 16, 2017. Of grave concern is the targeted elimination of the Fogarty International Center at NIH. This indiscriminate cut jeopardizes life-saving research required to end devastating global diseases like tuberculosis (TB) and HIV/AIDS, as well as malaria, dengue, and Ebola.